Cargando…
The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776433/ https://www.ncbi.nlm.nih.gov/pubmed/36551737 http://dx.doi.org/10.3390/cancers14246252 |
_version_ | 1784855864327274496 |
---|---|
author | Pereira, Sandrine Orlandi, Ester Deneuve, Sophie Barcellini, Amelia Chalaszczyk, Agnieszka Behm-Ansmant, Isabelle Hettal, Liza Rancati, Tiziana Vogin, Guillaume Thariat, Juliette |
author_facet | Pereira, Sandrine Orlandi, Ester Deneuve, Sophie Barcellini, Amelia Chalaszczyk, Agnieszka Behm-Ansmant, Isabelle Hettal, Liza Rancati, Tiziana Vogin, Guillaume Thariat, Juliette |
author_sort | Pereira, Sandrine |
collection | PubMed |
description | SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes the methods of individual radiation sensitivity (iRS) diagnosis, their impact on the RT workflow as well as initiatives to support clinical decision-making initiatives. ABSTRACT: (1) Background: radiotherapy is a cornerstone of cancer treatment. When delivering a tumoricidal dose, the risk of severe late toxicities is usually kept below 5% using dose-volume constraints. However, individual radiation sensitivity (iRS) is responsible (with other technical factors) for unexpected toxicities after exposure to a dose that induces no toxicity in the general population. Diagnosing iRS before radiotherapy could avoid unnecessary toxicities in patients with a grossly normal phenotype. Thus, we reviewed iRS diagnostic data and their impact on decision-making processes and the RT workflow; (2) Methods: following a description of radiation toxicities, we conducted a critical review of the current state of the knowledge on individual determinants of cellular/tissue radiation; (3) Results: tremendous advances in technology now allow minimally-invasive genomic, epigenetic and functional testing and a better understanding of iRS. Ongoing large translational studies implement various tests and enriched NTCP models designed to improve the prediction of toxicities. iRS testing could better support informed radiotherapy decisions for individuals with a normal phenotype who experience unusual toxicities. Ethics of medical decisions with an accurate prediction of personalized radiotherapy’s risk/benefits and its health economics impact are at stake; (4) Conclusions: iRS testing represents a critical unmet need to design personalized radiotherapy protocols relying on extended NTCP models integrating iRS. |
format | Online Article Text |
id | pubmed-9776433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97764332022-12-23 The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review Pereira, Sandrine Orlandi, Ester Deneuve, Sophie Barcellini, Amelia Chalaszczyk, Agnieszka Behm-Ansmant, Isabelle Hettal, Liza Rancati, Tiziana Vogin, Guillaume Thariat, Juliette Cancers (Basel) Review SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes the methods of individual radiation sensitivity (iRS) diagnosis, their impact on the RT workflow as well as initiatives to support clinical decision-making initiatives. ABSTRACT: (1) Background: radiotherapy is a cornerstone of cancer treatment. When delivering a tumoricidal dose, the risk of severe late toxicities is usually kept below 5% using dose-volume constraints. However, individual radiation sensitivity (iRS) is responsible (with other technical factors) for unexpected toxicities after exposure to a dose that induces no toxicity in the general population. Diagnosing iRS before radiotherapy could avoid unnecessary toxicities in patients with a grossly normal phenotype. Thus, we reviewed iRS diagnostic data and their impact on decision-making processes and the RT workflow; (2) Methods: following a description of radiation toxicities, we conducted a critical review of the current state of the knowledge on individual determinants of cellular/tissue radiation; (3) Results: tremendous advances in technology now allow minimally-invasive genomic, epigenetic and functional testing and a better understanding of iRS. Ongoing large translational studies implement various tests and enriched NTCP models designed to improve the prediction of toxicities. iRS testing could better support informed radiotherapy decisions for individuals with a normal phenotype who experience unusual toxicities. Ethics of medical decisions with an accurate prediction of personalized radiotherapy’s risk/benefits and its health economics impact are at stake; (4) Conclusions: iRS testing represents a critical unmet need to design personalized radiotherapy protocols relying on extended NTCP models integrating iRS. MDPI 2022-12-19 /pmc/articles/PMC9776433/ /pubmed/36551737 http://dx.doi.org/10.3390/cancers14246252 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pereira, Sandrine Orlandi, Ester Deneuve, Sophie Barcellini, Amelia Chalaszczyk, Agnieszka Behm-Ansmant, Isabelle Hettal, Liza Rancati, Tiziana Vogin, Guillaume Thariat, Juliette The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title | The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title_full | The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title_fullStr | The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title_full_unstemmed | The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title_short | The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review |
title_sort | normal, the radiosensitive, and the ataxic in the era of precision radiotherapy: a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776433/ https://www.ncbi.nlm.nih.gov/pubmed/36551737 http://dx.doi.org/10.3390/cancers14246252 |
work_keys_str_mv | AT pereirasandrine thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT orlandiester thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT deneuvesophie thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT barcelliniamelia thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT chalaszczykagnieszka thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT behmansmantisabelle thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT hettalliza thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT rancatitiziana thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT voginguillaume thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT thariatjuliette thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT pereirasandrine normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT orlandiester normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT deneuvesophie normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT barcelliniamelia normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT chalaszczykagnieszka normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT behmansmantisabelle normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT hettalliza normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT rancatitiziana normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT voginguillaume normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview AT thariatjuliette normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview |